clinical trial · NCT07037433
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Atherosclerotic Cardiovascular DiseaseOverweightObesityMaridebart CafraglutidePlacebo
brief summary
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
started
Jul 25, 2025
primary completion
Jun 30, 2028
completion
Sep 29, 2030
last updated
Jun 18, 2026
official title
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol